Baird downgrades Accenture stock rating to neutral on valuation

Baird downgraded Accenture to Neutral from Outperform but raised its price target to $252 from $245. It cited slower expected organic constant-currency growth of roughly 3%-4% in fiscal 2027-2029, versus an 8% fiscal 2014-2023 average, and lower projected free-cash-flow conversion of 110%+ in fiscal 2028-2029 versus a historical 125% average. Other firms remained more positive after fiscal Q4 2026 constant-currency revenue growth of 7% exceeded guidance of 1%-5%; Accenture targets about 3% organic growth in fiscal 2027-2028 and 5% in fiscal 2029.

Analysis

The key issue is whether ACN’s lower multiple reflects a temporary growth pause or a durable reset in organic growth and cash generation. If the latter, comparing today’s valuation with its prior-decade average is weak support for re-rating: slower growth, lower cash conversion and greater reliance on acquisitions can justify a structurally lower multiple. Acquisition spend also competes with buybacks and dividends, while deal-led revenue may obscure whether AI demand is creating durable, high-quality organic growth. AI could support bookings yet pressure pricing or utilization if productivity gains are passed through to clients.

The counterweight is execution: a strong quarter and any evidence that AI work converts into sustained revenue growth could make bearish positioning costly, particularly if expectations are already subdued. The cited analyst estimate cuts are a caution signal, not proof of a broader consensus reset. Near term, verify the October 14 investor-day disclosures and subsequent estimate revisions—the event date in the article has passed. Over 1–3 months, watch organic constant-currency growth, bookings-to-revenue conversion and guidance. Over 6–18 months, track cash conversion, acquisition returns and leverage. The thesis weakens if growth reaccelerates without acquisition dependence and cash conversion improves; it strengthens if guidance is cut or cash returns are crowded out. No outright short is compelling on this information alone.

Key Decisions for Investors

• Keep ACN at neutral/underweight rather than add on the historical-multiple argument. Before acting, review the October 14 investor-day transcript and verify whether analyst estimate revisions have stabilized.
• If ACN rallies without upward revisions to organic growth or cash-conversion expectations, consider a limited-risk 3–6 month put spread rather than an outright short; cap risk at the premium. Avoid entering before confirming the post-investor-day outlook and option pricing.
• Reassess for a long if subsequent results show sustained organic growth acceleration alongside improving free-cash-flow conversion, without a material increase in acquisition dependence. That would challenge the structural-reset thesis.
• Monitor quarterly organic constant-currency growth, bookings conversion, free-cash-flow conversion, acquisition contribution and net leverage. A guidance cut or weaker cash conversion supports the cautious view; sustained growth and cash improvement falsify it.